Drugs / F2H23H/DL001Z
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06431607 | May → Dec 2024 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F2H23H/DL001Z | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06431607 ↗ |
| Modality | Messenger RNA (mRNA) | “Flu mRNA study intervention F2H23H/DL001Z” NCT06431607 ↗ |
| Route | Intramuscular | “Study intervention was administered intramuscularly at Day 1.” NCT06431607 ↗ |